Fig 1.
Enrolment of patients with cryptococcosis from 25 enhanced surveillance sites into the nested cross-sectional study, October 2012 through February 2013.
Footnote: AmBd: amphotericin B deoxycholate. *Other reason: 10 (8%) no antifungal therapy was given; 3 (3%) AmBd was out of stock
Table 1.
Number of patients with cryptococcosis and number of physicians interviewed by enhanced surveillance site (hospital) category and South African province.
Table 2.
Comparison of patient outcome amongst those optimally monitored for nephrotoxicity, hypokalemia and anemia whilst receiving amphotericin B deoxycholate therapy for cryptococcosis.
Table 3.
Adherence to recommendations for prevention and monitoring of amphotericin B deoxycholate-related toxicities among patients with cryptococcosis (n = 524).
Table 4.
Univariate and multivariable analysis of factors associated with in-hospital outcome among patients treated with amphotericin B deoxycholate (n = 524).